Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

The effect of weight change on kidney cancer patients treated with targeted therapy

A recent retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) and on first- or second-line targeted therapy clinical trials showed that patients who experience weight loss during treatment have worse outcomes compared with patients with stable weight at 6 and 12 weeks of treatment. Weight loss at 6 weeks after the start […]

read more

Universal active surveillance for small renal masses

A study presented at the Society of Urologic Oncology (SUO) in Washington, USA last week concluded that universal initial active surveillance for patients with small renal masses (SRMs) less than 3 cm in diameter using predefined progression criteria can safely delay or avoid treatment for most patients. In the study, active surveillance was recommended for […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Prognostic implications of aquaporin 9 expression in kidney cancer

Water channel proteins, or aquaporins (AQPs) have been found in large amounts in tumour samples and have a role in the progression of cancer. This study looked at the messenger RNA (mRNA) expression for AQP9 and how this related to survival for patients with renal cell carcinoma (RCC). The data for this study came from […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

Panobinostat plus everolimus not effective in metastatic kidney cancer

A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]

read more

Avelumab as a first- or second-line treatment for metastatic kidney cancer

A recent study looked at the efficacy and safety of first- or second-line avelumab (an anti–PD-L1 immunotherapy) in patients with metastatic clear cell renal cell carcinoma (RCC). A total of 62 patients were treated with avelumab in the first-line (intravenous infusion every 2 weeks) and 20 patients were treated with avelumab in the second-line. Most […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more
Showing 1 to 10 of 51 results
  TOP